Medline Inc. announces pricing of secondary offering of Class A common stock
Northfield, Ill., November 17, 2026 (GLOBE NEWSWIRE) – Medline Inc. (Nasdaq: MDLN) (“Medline”) announced today the pricing of its secondary offering of 60,000,000 shares of Medline’s Class A common stock by certain selling stockholders affiliated with Blackstone Inc., The Carlyle Group Inc., Hellman & Friedman LLC along with GIC Private Limited and its managed affiliate and a wholly owned subsidiary of the Abu Dhabi Investment Authority (collectively, the “Selling Stockholders”) at a price to the public of $35.50 per share (the “Offering”). The Selling Stockholders have also granted the underwriters a 30-day option to purchase up to an additional 9,000,000 shares of Medline’s Class A common stock. The Offering is expected to close on November 23, 2026, subject to customary closing conditions.
Medline is not selling any shares of Class A common stock in the Offering and will not receive any of the proceeds from the sale.
Goldman Sachs & Co. LLC, Morgan Stanley, BofA Securities and J.P. Morgan are acting as global coordinators and joint bookrunning managers. Barclays, Citigroup, Deutsche Bank Securities, Jefferies, UBS Investment Bank, Evercore ISI, BMO Capital Markets, BNP Paribas, MUFG, RBC Capital Markets, Santander, Societe Generale, TD Cowen, Wells Fargo Securities, Wolfe | Nomura Alliance, Leerink Partners, Macquarie Capital, Mizuho, Piper Sandler, Truist Securities and William Blair are acting as bookrunning managers, and Blackstone Capital Markets, Carlyle, Baird, Rothschild & Co, Stifel, BTIG, ING, IMI – Intesa Sanpaolo, NCMG, Perella Weinberg, Academy Securities, Blaylock Van, LLC, C.L. King & Associates, Drexel Hamilton, Loop Capital Markets, Mischler AmeriVet, R. Seelaus & Co., LLC, Ramirez & Co., Inc., Siebert Williams Shank and Tigress Financial Partners are acting as co-managers for the Offering.
The Offering of these securities is being made only by means of a prospectus. When available, copies of the prospectus relating to this Offering may be obtained from: Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, by telephone at 1-866-471-2526, or by email at prospectus-ny@ny.email.gs.com; Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014 or by email at prospectus@morganstanley.com; BofA Securities, Attention: Prospectus Department, NC1-022-02-25, 201 North Tryon Street, Charlotte, NC 28255-0001 or by email at dg.prospectus_requests@bofa.com; and J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by email at prospectus-eq_fi@jpmchase.com and postsalemanualrequests@broadridge.com.
In addition, as previously announced, Medline and Medline Holdings, LP (“Medline Holdings”) have agreed to repurchase an aggregate of $200 million of Medline’s Class A common stock and limited partnership interests of Medline Holdings (“Common Units”) directly from the Selling Stockholders in a private, non-underwritten transaction at a price per equity interest equal to the price paid by the underwriters in the Offering (the “Repurchase”). To the extent that Common Units are repurchased from a Selling Stockholder, upon closing of the Repurchase, such Selling Stockholder will also transfer an equivalent number of shares of Medline’s Class B common stock to Medline for no additional consideration, and such shares of Class B common stock will be cancelled and retired. The Repurchase is expected to close concurrently with the Offering and is conditioned upon the closing of the Offering. The closing of the Offering is not conditioned upon the closing of the Repurchase. The Repurchase has been approved by the Audit Committee of Medline’s Board of Directors and is pursuant to, and will count toward, Medline’s previously announced share repurchase program.